Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria

Emerging Infectious Diseases

Volumn 19, Issue 5, 2013, Pages 802-805

  Bright, Taylor ^a   Alenazi, Thamer ^b,c   Shokoples, Sandra ^d   Tarning, Joel ^e   Paganotti, Giacomo M ^f   White, Nicholas J ^e   Houston, Stanley ^b,c   Winzeler, Elizabeth A ^a   Yanow, Stephanie K ^d,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d Provincial Laboratory for Public Health   (Canada)

^e MAHIDOL UNIVERSITY   (Thailand)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CYTOCHROME P450 2D6; PRIMAQUINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; DNA SEQUENCE; DRUG TOLERANCE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOME; GENOTYPE; HUMAN; KNOCKOUT GENE; MALE; MICROSCOPY; PARASITE ISOLATION; PLASMODIUM VIVAX MALARIA; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE VARIANT;

GENETICS; MALARIA; PARASITES; PLASMODIUM VIVAX; PRIMAQUINE; RELAPSE;

ADULT; ANTIMALARIALS; BIOTRANSFORMATION; CHLOROQUINE; DRUG TOLERANCE; GENOME, PROTOZOAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMAQUINE; RECURRENCE; SEQUENCE ANALYSIS, DNA;

EID: 84876779640     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1905.121852     Document Type: Article

References (15)

1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774. http://dx.doi.org/10.1371/journal.pntd.0000774
2. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430-5. http://dx.doi.org/10.1097/QCO.0b013e32832f14c1
3. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508-34. http://dx.doi.org/10.1128/CMR.00008-09
4. Chiang TY, Lin WC, Kuo MC, Ji DD, Fang CT. Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses. Clin Microbiol Infect. 2012;18:E232-4. http://dx.doi.org/10.1111/j.1469-0691.2012.03820.x
5. Townell N, Looke D, McDougall D, McCarthy JS. Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. Malar J. 2012;11:214. http://dx.doi.org/10.1186/1475-2875-11-214
6. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380-8. http://dx.doi.org/10.1086/338566
7. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 2003;49:977-89. http://dx.doi.org/10.1046/j.1365-2958.2003.03627.x
8. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403:906-9. http://dx.doi.org/10.1038/35002615
9. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S,et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat Genet. 2012;44:1046-50. http://dx.doi.org/10.1038/ng.2373
10. Ribeiro V, Cavaco I. Pharmacogenetics of cytochromes P450 in tropical medicine. Curr Drug Targets. 2006;7:1709-19. http://dx.doi.org/10.2174/138945006779025347
11. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259. http://dx.doi.org/10.1186/1475-2875-11-259
12. Paganotti GM, Gallo BC, Verra F, Sirima BS, Nebie I, Diarra A, et al. Human genetic variation is associated with Plasmodium falciparum drug resistance. J Infect Dis. 2011;204:1772-8. http://dx.doi.org/10.1093/infdis/jir629
13. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-43. http://dx.doi.org/10.1517/14622416.3.2.229
14. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402-15.
15. Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem. 2009;284:7687-96. http://dx.doi. org/10.1074/jbc.M806944200